cxcl10 levels  (R&D Systems)

Journal: bioRxiv

Article Title: Dose-dependent interferon programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination

doi: 10.1101/2025.08.15.668720

Figure Lengend Snippet: (A) Study design. Blood samples were collected longitudinally from individuals (n = 31) vaccinated with either two doses of mRNA vaccines (Pfizer-BioNTech, Moderna) or a single dose of the adenovirus-based Johnson & Johnson (J&J) vaccine. Antibody titers were measured before and 3–4 weeks after each vaccination. A subset of donors (6 Pfizer, 6 Moderna, 3 J&J) was selected for in-depth profiling, including serum cytokine analysis and DOGMA-seq. Age distributions among vaccine groups were compared using the Kruskal–Wallis test. (B) IgG titers against SARS-CoV-2 spike protein measured by ELISA before and after vaccination. Antibody titers further increased after the mRNA booster dose. (C) Serum levels of CXCL10 and IFN-γ at key time points were quantified using ELLA. Both cytokines increased on day 1 (D1) after the adenoviral vaccine and following the mRNA booster dose. (D–E) UMAP projections of DOGMA-seq data for transcriptome (D, scRNA-seq) and chromatin accessibility (E, scATAC-seq) modalities. Canonical lineage markers (surface protein and gene expression) annotated major immune cell populations. (B), (C) Statistical significance was assessed using two-tailed paired t-tests: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

Article Snippet: The first dose of mRNA vaccines modestly elevated CXCL10 levels at day 1 ( p = 0.14 for Moderna, p = 0.013 for Pfizer), while the second dose induced stronger induction of both CXCL10 and IFN-γ (CXCL10: p = 0.019 for Moderna, p = 0.00036 for Pfizer; IFN-γ: p = 0.019 for Moderna, p = 0.0125 for Pfizer, ).

Techniques: Vaccines, Enzyme-linked Immunosorbent Assay, Gene Expression, Two Tailed Test

Journal: Clinical Cancer Research

Article Title: XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

doi: 10.1158/1078-0432.CCR-24-2449

Figure Lengend Snippet: XMT-2056 elicits potent antigen-dependent and Fc-R–mediated activation of monocytes in cocultures. A, Schematic of the XMT-2056 mechanism, which includes HER2-dependent ADC uptake into tumor cells and Fcγ-R–expressing myeloid cells. B, Chemical structure of XMT-2056. C, Cytokine induction as measured by a multiplex Luminex assay from supernatants of fresh human WBCs treated for 6 (IFN-β) or 24 (CXCL10, IL-6, and TNF-a) hours. Bars represent mean value of n = 2 data points shown as symbols. D, Competition with trastuzumab by biolayer interferometry (Octet): trastuzumab was loaded onto the sensor chip, and HER2 ECD or HT19 antibody associations are indicated by blue arrows. Additional binding by HT19 indicates noncompetitive binding. E, Competition with trastuzumab by cell-based flow cytometry. HT19 hIgG1 or mIgG2a formats detected with either Alexa Fluor anti-hIgG1 (h647) or Alexa Fluor anti-mIgG2a (m647) secondary antibodies in the presence or absence of trastuzumab–mIgG2a. Each point represents the mean and SD ( n = 3). F, Binding of XMT-2056 or HT19 antibody to HCC1954 cells showing fluorescence intensities measured by flow cytometry. Each point represents the mean and SD ( n = 2). G, CXCL10 cytokine induction in HCC1954 monocultures treated for 24 hours with XMT-2056, nonbinding control ADC, HT19, or the free payload. Each point represents the mean and SD ( n = 2). H, Binding of XMT-2056 or Fc-mutant XMT-2056, HT19, and nonbinding control ADC to SKOV3 cells showing fluorescence intensities measured by flow cytometry. Each point represents the mean and SD ( n = 3). I and J, IRF3 reporter activity of THP1 cells in coculture with SKOV3 cells ( I ) or cultured on recombinant HER2 antigen-coated plates ( J ) treated for 24 hours with XMT-2056 or Fc-mutant XMT-2056, nonbinding control ADC, or STING agonist payload. Each point represents the mean and SD ( n = 3). When noted, EC 50 and B max values represent mean of two independent experiments. gMFI, geometric mean fluorescence intensity; RLU, relative light units. ( A, Created in BioRender. Cetinbas, N. [2025], https://BioRender.com/s16c825 ; G, Created in BioRender. Cetinbas, N. [2025], https://BioRender.com/s16c825 ; I and J, Created in BioRender. Cetinbas, N. [2025], https://BioRender.com/s16c825 .)

Article Snippet: Culture supernatants were collected, and CXCL10 levels were measured by ELISA using Mouse CXCL10/IP-10 DuoSet ELISA Kit (R&D Systems, Cat. DY466) following the manufacturer’s recommended procedures.

Techniques: Activation Assay, Expressing, Multiplex Assay, Luminex, Binding Assay, Flow Cytometry, Fluorescence, Control, Mutagenesis, Activity Assay, Cell Culture, Recombinant

Journal: BMC medicine

Article Title: Neutrophil extracellular trap-induced intermediate monocytes trigger macrophage activation syndrome in adult-onset Still's disease.

doi: 10.1186/s12916-023-03231-9

Figure Lengend Snippet: Fig. 2 Cell-surface markers of monocyte subsets in patients with AOSD. A MFI (median fluorescence intensity) of CD80, CD86, HLA-DR, and CD163 for three monocyte subsets. B MFI of CD80, CD86, HLA-DR, and CD163 on total monocytes from AOSD patients and HCs. C MFI of CD80, CD86, HLA-DR, and CD163 on IMs from AOSD patients and HCs. D Immunofluorescence images and detection of phagocytic activity of CMs and IMs. E The proportion of Th1, Th17, and Treg cells after coculture of CD4 + T cells with CMs or IMs. F The concentrations of IL-1β, IL-6, TNF, CCL8, and CXCL10 in the cell supernatants of CMs and IMs. The results show the means ± SD. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001, ns = not significance, by ANOVA test followed by Tukey’s test for multiple comparisons in A, E, and F or by Mann–Whitney U test in B and C

Article Snippet: CCL8 and CXCL10 levels in plasma and cell supernatants were measured by commercial sandwich enzyme-linked immunosorbent assay (ELISA, Cusabio, China) following the manufacturer’s instructions.

Techniques: Fluorescence, Immunofluorescence, Activity Assay, MANN-WHITNEY

Journal: EBioMedicine

Article Title: High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.

doi: 10.1016/j.ebiom.2023.104883

Figure Lengend Snippet: Fig. 2: Systemic (serum) levels of CXCL10 in SSc without ILD (N = 124), SSc-ILD (N = 41) and healthy controls (N = 13). Patients with SSc with or without interstitial lung disease have statistically significant higher CXCL10 levels compared to healthy controls (Mann–Whitney U test). Patients with SSc-ILD had statistically sig- nificant higher levels of CXCL10 compared to SSc without ILD (Mann–Whitney U test). Measurements are shown as median values (dashed) with IQR (dotted) in pg/ml.

Article Snippet: Local CXCL10 protein levels were assessed by ELISA (R&D systems, DY266, MN, USA) according to manufacturer’s instructions and as described previously.24,25 Highperformance ELISA buffer (product no.: M1940, Sanquin, Amsterdam, The Netherlands) was used during serum incubation to prevent non-specific reactions.

Techniques: MANN-WHITNEY

Journal: EBioMedicine

Article Title: High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.

doi: 10.1016/j.ebiom.2023.104883

Figure Lengend Snippet: Fig. 3: CXCL10 levels were negatively correlated with PFTs in patients with SSc-ILD. a) Spearman’s correlation between serum CXCL10 and %FVC shows a moderate negative correlation (N = 38, r = −0.43, P = 0.012. b) Spearman’s correlation between serum CXCL10 and %DLco indicates no correlation (N = 32). After adjusting for confounders, CXCL10 was negatively associated with %DLco. PFTs: pulmonary function tests, FVC: forced vital capacity, DLco: capacity for carbon monoxide diffusion.

Article Snippet: Local CXCL10 protein levels were assessed by ELISA (R&D systems, DY266, MN, USA) according to manufacturer’s instructions and as described previously.24,25 Highperformance ELISA buffer (product no.: M1940, Sanquin, Amsterdam, The Netherlands) was used during serum incubation to prevent non-specific reactions.

Techniques: Diffusion-based Assay

Journal: EBioMedicine

Article Title: High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.

doi: 10.1016/j.ebiom.2023.104883

Figure Lengend Snippet: Fig. 4: Higher CXCL10 may be associated with long-term ILD development. Kaplan–Meier survival curve according to baseline median CXCL10 concentration. CXCL10 levels >78.5 pg/ml shows a 2.74-fold increased hazard of new onset of ILD [Log-rank (Mantel-cox) test, P = 0.119].

Article Snippet: Local CXCL10 protein levels were assessed by ELISA (R&D systems, DY266, MN, USA) according to manufacturer’s instructions and as described previously.24,25 Highperformance ELISA buffer (product no.: M1940, Sanquin, Amsterdam, The Netherlands) was used during serum incubation to prevent non-specific reactions.

Techniques: Concentration Assay

Journal: EBioMedicine

Article Title: High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.

doi: 10.1016/j.ebiom.2023.104883

Figure Lengend Snippet: Fig. 5: Local CXCL10 concentration levels and correlation between local and systemic CXCL10 levels. a) Comparison between CXCL10 concentration levels in BAL supernatant between SSc-without-ILD (N = 8) and patients with SSc-ILD (N = 6) (Mann–Whitney U test, P = 0.23). Measurements are shown as median values (dashed) with IQR (dotted) in pg/ml. b) Spearman’s correlation between CXCL10 concentration levels in serum and BAL supernatant in the same patients showing statistical significance P = 0.007 and r = 0.7 (N = 14). Measurements are in pg/ml.

Article Snippet: Local CXCL10 protein levels were assessed by ELISA (R&D systems, DY266, MN, USA) according to manufacturer’s instructions and as described previously.24,25 Highperformance ELISA buffer (product no.: M1940, Sanquin, Amsterdam, The Netherlands) was used during serum incubation to prevent non-specific reactions.

Techniques: Concentration Assay, Comparison, MANN-WHITNEY

Journal: EBioMedicine

Article Title: High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.

doi: 10.1016/j.ebiom.2023.104883

Figure Lengend Snippet: Fig. 6: CXCL10 gene expression in SSc-ILD inflammatory and fibrotic regions. Transcriptomic analysis showed that CXCL10 is 2.3x more highly expressed in inflammatory regions compared with fibrotic regions in patients with SSc-ILD [P = 0.029 (t-test)]. N = 11 (5 in- flammatory SSc-ILD regions and 6 fibrotic SSc-ILD regions).

Article Snippet: Local CXCL10 protein levels were assessed by ELISA (R&D systems, DY266, MN, USA) according to manufacturer’s instructions and as described previously.24,25 Highperformance ELISA buffer (product no.: M1940, Sanquin, Amsterdam, The Netherlands) was used during serum incubation to prevent non-specific reactions.

Techniques: Gene Expression

Journal: EBioMedicine

Article Title: High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.

doi: 10.1016/j.ebiom.2023.104883

Figure Lengend Snippet: Fig. 7: Stimulation of normal human lung fibroblasts with SSc fluids (a–d), or inflammatory or fibrotic cytokines (e). (a–d) 5% BAL supernatant from SSc without ILD (BAL SSc) or SSc-ILD (BAL SSc-ILD), or 1% serum from SSc without ILD (SSc serum) or SSc-ILD (SSc-ILD serum) or healthy control (Pool serum) was used to stimulate lung fibroblasts. (a) SSc-ILD BAL and serum-treated fibroblasts overexpressed cxcl10 compared to SSc without ILD BAL (Mann–Whitney U test, P = 0.004) and serum (Mann–Whitney U test, P = 0.0087). Also, SSc-ILD BAL-treated fibroblasts had higher cxcl10 levels compared to CTRL (Mann–Whitney U test, P = 0.0022). Fibroblasts treated with SSc-ILD serum significantly overex- pressed cxcl10 compared to fibroblasts treated with healthy serum (Mann–Whitney U test, P = 0.0022). SSc-ILD serum-treated lung fibroblasts overexpressed ctgf expression compared to SSc without ILD and pool sera (Mann–Whitney U test, P = 0.026 and P = 0.0087, respectively). (c–d) No statistically significant differences in tgfβ or αsma expression when lung fibroblasts were treated with BAL or serum (Mann–Whitney U test). The results are medians of three technical experiments (n = 3) where 6 patients’ biofluids were used (N = 6). (e) IL-6 (10 ng/ml or 100 ng/ml) or TGF-β (10 ng/ml) or both were used to stimulate lung fibroblasts for 4 h. IL-6 stimulated cxcl10 expression in lung fibroblasts in a concentration-dependent manner. The higher concentration of IL-6 (100 ng/ml) showed increase of cxcl10 expression with a trend towards statistical significance of P value = 0.055 vs. CTRL (Mann–Whitney U test). The results are medians with IQR of three technical experiments (n = 3). CTRL: culture media without stimulant.

Article Snippet: Local CXCL10 protein levels were assessed by ELISA (R&D systems, DY266, MN, USA) according to manufacturer’s instructions and as described previously.24,25 Highperformance ELISA buffer (product no.: M1940, Sanquin, Amsterdam, The Netherlands) was used during serum incubation to prevent non-specific reactions.

Techniques: Control, MANN-WHITNEY, Expressing, Concentration Assay